Reckitt Benckiser Group plc is a consumer health and hygiene company founded in 1840. The business operates across four categories: Germ Protection, Household Care, Intimate Wellness, and Self Care. Key brands include Dettol, Harpic, Gaviscon, Mucinex, Strepsils, and Mead Johnson. The company serves individual consumers, families, and communities across developed and emerging markets. Reckitt partners with organizations such as the Aga Khan Foundation for social impact initiatives and operates a global innovation program called Reckitt Catalyst. The company divested its Russia Hygiene business and has received U.S. FDA approval for Mucinex 12HR Cold & Fever Multi-Symptom.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Household & Personal Products Homepage reckitt.com
Sector Consumer Defensive IR page reckitt.com/investors
Tags
consumer health, hygiene, germ protection, household care, intimate wellness, self care, over-the-counter medicines, infant nutrition, oral care, digestive health, Dettol, Harpic, Gaviscon, Mucinex, Strepsils, Mead Johnson, Reckitt Catalyst
Press page reckitt.com/news

Metrics

Valuation  
Market cap £ 33.52B
Market cap (USD) $ 44.336B
P/E 11.63
PEG 1.06
P/BV 5.88
P/S 2.46
P/OCF 14.59
P/FCF 19.03
Dividend yield —
Turnover / mcap —
Returns  
ROE 44.0%
ROI 20.7%
ROIC 22.9%
Profit margin 22.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 11.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 97.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 14.205B 14.169B 14.607B 14.453B 13.234B 13.993B 12.846B 12.597B 11.512B 9.48B 8.874B 8.836B 10.043B 9.567B
Net profit 3.187B 1.428B 1.657B 2.349B -21M 1.203B -3.67B 2.181B 6.189B 1.836B 1.745B 3.224B 1.74B 1.825B
Free cash flow 1.761B 2.312B 2.288B 2.035B — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 58.67 49.08 56.96 61.16 56.92 59.65 — — — — — — — —
Price performance 12m 0.2 -0.14 -0.07 0.07 -0.05 — — — — — — — — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (GBP) 1.92B 1.93B 2.08B 2.06B 2.09B 2.12B
↳ YoY growth +0.3% +8.1% -1.0% +1.4% +1.6%
↳ 5y CAGR +2.0%
Borrowings, current (GBP) 763M 2.49B 1.72B 1.68B 1.42B 810M
Borrowings, non-current (GBP) 9.79B 7.08B 7.16B 6.86B 7.24B 7.62B
Cash and deposits (GBP) 1.65B 1.26B 1.16B 1.39B 880M 1.95B
Net debt (borrowings + leases - cash) (GBP) 8.91B 8.3B 7.73B 7.15B 7.78B 6.48B
Cash flow detail
Operating cash flow (GBP) — 1.7B 2.4B 2.64B 2.68B 2.3B
Purchases of property, plant and equipment (GBP) -394M -373M -362M -348M -370M -536M
Purchases of intangible assets (GBP) -92M -77M -81M -101M -95M -79M
Change in receivables (cash effect) (GBP) 94M -130M -23M -87M -133M -144M
Change in inventories (cash effect) (GBP) -317M -57M -254M 118M 61M -196M
Dividends paid (cash effect) (GBP) -1.24B -1.25B -1.25B -1.34B -1.38B -1.4B
Share buybacks (cash effect) (GBP) -4M -5M 0.00 -2M -3M -3M
Interest paid (cash effect) (GBP) -323M -251M -243M -293M -350M -344M
Income taxes paid (cash effect) (GBP) -762M -915M -831M -922M -700M -897M
Share-based compensation (GBP) 15M 30M 78M 102M 85M 101M
Operating cash flow before change in receivables (GBP) — 1.83B 2.42B 2.72B 2.82B 2.44B
Free cash flow (OCF - PPE - intangibles) (GBP) — 1.25B 1.95B 2.19B 2.22B 1.68B
Income detail
Total comprehensive income (GBP) 863M -699M 3.18B 854M 1.06B 2.82B
Comprehensive income to owners (GBP) 797M -741M 3.16B 841M 1.06B 2.81B
Reported Apr 27, 2022 Mar 28, 2023 Mar 28, 2023 Apr 5, 2024 Mar 26, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

By combining trusted science, consumer insight and global scale, Veet has evolved from a single depilatory cream into the world's leading depilatory brand

News Powerbrands Brands Veet

4 minutes read

Veet banner featuring a woman applying hair removal cream to her leg

Today, Veet is the world’s leading depilatory brand*, available in more than 80 countries, trusted by more than 30 million consumers. Every second, three Veet cream tubes are sold.

In 2025, the brand delivered double-digit growth across regions, with Emerging Markets leading momentum, demonstrating how more than a century of consumer-led innovation continues to create value today.

That success is built on understanding consumers deeply, evolving with their changing routines and turning local insights into innovations that can scale globally.

Evolving with consumers for more than a century

Veet’s story began in 1919 in Canada with the launch of Neet, entering a market where hair removal was still a developing category. At the time, existing methods were often slow, inconvenient and difficult to use, creating an opportunity for a simpler, more accessible solution.

Later renamed Veet, from the French word “vite”, meaning “quickly”, the brand built its early reputation by delivering a faster and more convenient approach to hair removal.

But as beauty routines, lifestyles and cultural attitudes evolved, so did consumer expectations. Over the decades, consumers began looking for solutions tailored to different skin types, body areas, preferences and occasions, moving beyond a single approach to beauty and grooming.

At Reckitt, these changing expectations have continually shaped how we innovate Veet. What began as a depilatory cream has grown into a comprehensive portfolio designed around the many ways consumers approach hair removal today.

Today, Veet’s broader grooming platform spanning hair removal creams, cold and hot wax, specialist solutions, trimming and post-hair removal care, gives consumers more options to find the right solutions for their skin, body area and routine.

Veet Infographic

Turning local insight into global growth

While Veet’s century of evolution has created a strong foundation, becoming a global leader has also required understanding that consumers have different relationships with beauty, grooming and self-care.

China illustrates this approach.

The Veet Bikini depilatory cream delivered a step-change in Veet’s ability to capture unmet consumer needs, reinforcing brand leadership and driving category growth in China in 2025. By opening up new usage occasions, the launch strengthened Veet’s position in a growing depilatory market while supporting continued growth of the core portfolio.

Veet Bikini contributed around 80% of the brand’s growth, while the base business also continued to grow, underlining the strength of Veet’s overall market position and historical share. The launch was supported by a digital-led execution across livestreaming, social commerce and creator partnerships, driving awareness through channels aligned to evolving consumer behaviours.

“The most successful innovations create new reasons to engage with the category. Veet Bikini is a great example of how understanding local consumer needs and embracing a social-first activation can unlock entirely new depilation occasions, driving growth for both the innovation and the broader brand portfolio.”

Marine Grataloup

Veet’s Global Brand Director

More than a century after its launch, Veet continues to evolve by putting consumers at the heart of innovation. By combining trusted science, local insight and global scale, Reckitt continues to strengthen Veet’s leadership and build the next generation of growth.

Winning the Digital Shelf: How Veet Is Turning China's Best Practices into Global Growth

As consumer discovery, trial and purchase journeys migrate online, brands that master the digital ecosystem gain a decisive advantage. Veet has successfully adapted its best practices from China.

In the U.S., Veet is delivering high double-digit growth by executing against a simple but powerful formula: win where consumers discover, shop and buy. Through best-in-class digital shelf execution, retail media and performance marketing, Veet has strengthened its visibility and conversion across key online retailers. A standout example is the 2-Minute Gel Cream, which has earned Amazon Overall Pick status and become a consumer favorite, helping recruit new shoppers into the brand while reinforcing Veet's superiority credentials.

Inspired by China's seamless integration of content and commerce, Veet has built a strong presence on TikTok through creator partnerships and TikTok Shop activation. Influencers drive authentic product demonstrations, while frictionless purchasing allows consumers to move from discovery to checkout within seconds.

Importantly, the impact extends beyond e-commerce. TikTok Shop has become a powerful trial and awareness engine, creating a meaningful halo effect on offline sales as consumers seek out Veet products across retail channels after discovering them on social platforms.

The result is a modern growth model where retail excellence, performance marketing and social commerce work together to drive penetration. What started as inspiration from China is now proving its power in the U.S., creating a blueprint that Veet can scale across markets worldwide.

Our brands latest news

Stories from our brands – across the globe. Take a look at our programmes and partnerships, innovations and investments that are making a difference in our consumers lives.

See more stories

5 minutes read

News

19 Oct 2026

Disrupting the cold and flu category with a breakthrough innovation

How Mucinex redefined cold and fever relief

3 minutes read

Gaviscon Double Action products in mint and peppermint flavours

News

02 Sep 2026

From A Simple Scientific Question To The World’s Go-To Heartburn & Indigestion Brand

How Gaviscon grew to define digestive self-care

4 minutes read

Children and community members at a Dettol Climate Resilient School in India

News

10 Aug 2026

How Dettol’s Climate Resilient Schools Programme is improving child health in India

5 minutes read

A box of Mucinex 12HR Cold & Fever Multi-Symptom medicine centered on a vibrant pink background, surrounded by four large bi-layer tablets

News

05 Aug 2026

Reckitt Announces U.S. FDA Approval of Mucinex 12HR Cold & Fever Multi-Symptom, the First OTC Innovation in the Cold & Flu Category in 14 Years

Company’s First New Drug Approval Addresses #1 Unmet Need for Long-Lasting Symptom Relief*

5 minutes read

Worker sorting red lozenges on a production line next to a Strepsils tin

Brands

09 Jun 2026

How unique science and consumer obsession are expanding Strepsils’ reach

A new era of dual action science is taking Strepsils beyond sore throat

5 minutes read

Collage of Dettol cleaning and skincare products with family photos.

Brands

09 Jan 2026

Dettol - A legacy of global impact

Lifting the lid on the past, present and future of one of the world’s most trusted brands

4 minutes read

Meet Our Powerbrands

Brands

03 Apr 2025

Meet Our Powerbrands

The Foundations for Success

5 minutes read

Lysol Air Sanitizer scoops a R&D100 Award!

Brands

02 Sep 2024

Lysol Air Sanitizer scoops a R&D100 Award!

103 - 105 Bath Road, Slough Berkshire, SL1 3UH


© Reckitt 2026 All Rights Reserved

Edit

Cookies On This Site

We, RB UK Commercial Limited., use essential cookies to enable this site to function and to save some of your preferences.  We and our partners also use other, non-essential cookies and similar technologies to enhance the site’s functionality, improve your browsing experience, perform analytics, and offer you personalised advertising. You can accept all non-essential cookies, reject all non-essential cookies, or select “Manage cookie preferences” below for further options and information. We will retain your choice for 13 months. In the case of ”Essential” cookies, we automatically place them as permitted by applicable law.  To learn more about our cookie usage and how you can change your cookie settings, please read our Cookie Policy. To change your preferences, click on the green cookie icon at the bottom left of our site at any time.

Accept Non-Essential Cookies

Reject Non-Essential​ Cookies

Manage Preferences

Company Logo

Privacy Preference Centre

Privacy Preference Centre

  • About Cookies On This Site

  • Essential Cookies

  • Analytics Cookies

  • Advertising Cookies

About Cookies On This Site

We, RB UK Commercial Limited., use essential cookies to enable this site to function and to save some of your preferences.  We and our partners also use other, non-essential cookies and similar technologies to enhance the site’s functionality, improve your browsing experience, perform analytics, and offer you personalised advertising. You can accept all non-essential cookies, reject all non-essential cookies, or select “Manage cookie preferences” below for further options and information. We will retain your choice for 13 months. In the case of ”Essential” cookies, we automatically place them as permitted by applicable law.  To learn more about our cookie usage and how you can change your cookie settings, please read our Cookie Policy.   To change your preferences, click on the green cookie icon at the bottom left of our site at any time. 

Third-Party Partners

We work with trusted third-party partners. See below for more details on each.

Google

Purpose: Site functionality, visitor statistics, site traffic analysis, analysis of online user browsing behaviour

Privacy Policy: https://policies.google.com/privacy

Essential Cookies

Always Active

We use essential cookies to make our site work.  These cookies enable core site functionality, ensure the site is secure, allow us to manage the network and manage your consent preferences. These cookies cannot be disabled because without these cookies, the site cannot function properly. For example, these cookies may be used for site navigation, ensuring online forms work, allowing you to log in, or remembering your consent preferences.

Cookie Details

Analytics Cookies

Analytics Cookies

These cookies allow us to monitor our site usage. They count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.   If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

Cookie Details

Advertising Cookies

Advertising Cookies

These cookies may be set up by us or by our advertising partners. These cookies allow us or our partners to build a profile of your interests and show you relevant adverts on other sites.  The use of these cookies may involve tracking, targeting, and re-engaging you across multiple sites and social networks. If you disable these cookies, you will still see advertisements, however, they will not be personalised to your interests. 

Cookie Details

Back Button

Vendors List

Filter Button

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Confirm My Choices

Reject Non-Essential​ Cookies Accept Non-Essential Cookies

Powered by Onetrust

Disrupting the cold and flu category with a breakthrough innovation Bull 2 Bear 0 Product/operations

How Mucinex redefined cold and fever relief

News Powerbrands Brands Mucinex

5 minutes read

Summary

  • The first FDA (Food and Drug Administration) approved OTC medication developed to meet consumer demand for longer-lasting cold and fever symptom relief* for 12 hours
  • A patented breakthrough combining three active ingredients in one category-first formulation
  • The first FDA-approved innovation in the cold and flu category in 14 years marking Reckitt's first approved New Drug Application (NDA)

For decades, cold and flu symptoms have often outlasted the relief from over-the-counter medicines. While symptoms can persist throughout the day and night, many treatments require consumers to re-dose every few hours, creating disruption at a time when they need relief most.

Consumer research showed that 64% of people wanted longer-lasting symptom relief with fewer interruptions.

For Reckitt, this represented a clear unmet consumer need and an opportunity to redefine cold and fever symptom management. Teams across R&D, Commercial, Regulatory Supply and Quality came together with a bold ambition to develop a solution that could deliver long-lasting, multi-symptom relief in one dose.

What followed was more than a decade of development, research, problem-solving and collaboration. The challenge was complex combining three active ingredients with different characteristics to work together in harmony in a single tablet to deliver immediate release and long lasting relief from cold and fever symptoms.

A woman sitting on a sofa, using a tissue to relieve sneezing in a cozy home setting

No over the counter medicine had achieved this before.

Ryan Dullea

“At Reckitt, we believe the best innovations start with a deep understanding of unmet consumer needs. This innovation reflects years of scientific expertise and cross-functional collaboration to solve a challenge that mattered to consumers and had not previously been addressed in the category.”

Ryan Dullea

Chief Category Growth Officer

Scientists collaborating on research and product development in a modern laboratory

With that ambition in mind, teams across the business set out to tackle a challenge that had never been solved before, delivering long-lasting cold and fever symptom relief in a single dose. 

Mucinex, the No. 1 physician-trusted brand, has been innovating in cold and flu symptom relief since its launch in 2002. Over more than two decades, it has built a portfolio of more than 60 products spanning chest congestion relief, cough suppression, multi-symptom relief and fever and pain management. Its innovation has also extended across formats from tablets and liquids to nasal sprays, lozenges and children’s liquids and soft chews, giving the brand expertise across symptoms, needs and occasions.

Building on that expertise, scientists at Reckitt's Science and Innovation Centre in Hull, UK, turned to developing a formulation that could tackle multiple symptoms and longer relief.

"We attempted to bring an innovation to the consumer which hadn't been developed yet."

Tim Shea

Senior Medical Scientist, Upper Respiratory

Three challenging actives, one breakthrough

The objective was clear but difficult to formulate – one tablet containing three actives, each with a different job to do.

  • Guaifenesin

    An expectorant that loosens mucus and helps relieve chest congestion.

  • Dextromethorphan HBr

    A cough suppressant that helps control the cough reflex.

  • Naproxen sodium

    An NSAID (nonsteroidal anti-inflammatory drug) that helps reduce fever and relieve body aches, caused by inflammation.

Close-up of pink and white tablets being processed in pharmaceutical manufacturing equipment

Each active worked differently in the body, so the challenge was making sure they worked together in the right way, releasing at the right time to provide relief for 12 hours.

The tablet was designed to replicate the drug release profile for the existing four-hour products on the market, delivering an initial immediate release of actives followed by controlled release over time to provide sustained relief for 12 hours.

That complexity shaped the innovation.

The result was a patented bi-layer caplet that uses dual-release technology to control the release of ingredients over time to bring immediate and extended release. The formulation is designed to start relief and keep it going for 12 hours.

"The breakthrough moment was that we could actually prove in clinical studies that the product lasted twelve hours."

Sapphira Parrott

R&D Quality Manager

Mucinex® 12HR Cold & Fever Multi-Symptom became the first OTC medication to help relieve fever, body ache, cough, excess mucus and chest congestion for 12 hours.

From lab to launch

Proving the science was a major milestone. Bringing Mucinex 12HR Cold & Fever to consumers came with more challenges.

"We had everything you could possibly think of thrown at the project." says Kris Hall, R&D Senior Manager, Cold & Flu Mucinex.

Clinical trials were disrupted by the COVID-19 pandemic. Volcanic ash clouds and fire at a supplier’s factory created supply chain disruptions. Then the manufacturing team also experienced a product stability setback forcing them to rethink production and packaging approaches to ensure the caplet could be scaled from a handful to millions, consistently.

Then after Food and Drug Administration (FDA) reviewed the data, it requested additional evidence for the 12-hour claim. The team responded on an expedited timeline.

In December 2025, the FDA approved Mucinex 12HR Cold & Fever Multi-Symptom. It was the first New Drug Application (NDA) approved in the cold and fever category in 14 years and a category first OTC medication to help reduce fever, and relieve body ache, cough, excess mucus and chest congestion for 12 hours.

It was also the first FDA-approved NDA under the Reckitt name, marking a significant milestone for both brand and the category. 

A close-up of a person holding a Mucinex 12-hour cold and fever multi-symptom relief package

A Mucinex promotional team posing beside a branded cold and flu display in a pharmacy

Breakthrough to benchmark

Sixteen internal teams worked across formulation, clinical, regulatory, manufacturing and commercial development. Each played a part in taking up innovation from formulation and testing through approvals, scale-up and launch.

"Working together as one global team, we developed a first-of-its-kind OTC medication for the number one unmet need in the category." says Chloe Druskin, Brand Manager, Mucinex.

The journey from consumer insight to an FDA-approved medicine took more than a decade of science. It shows what can happen when an unmet consumer need is matched with commitment and cross-functional collaboration.

Ultimately, it is about turning a consumer need into better solutions and helping deliver better health in more hands, every day.

*Clear C&F U&A 2022

Our brands latest news

Stories from our brands – across the globe. Take a look at our programmes and partnerships, innovations and investments that are making a difference in our consumers lives.

See more stories

4 minutes read

Veet banner featuring a woman applying hair removal cream to her leg

News

22 Oct 2026

How Veet Turned Consumer Insight into a Century of Growth

By combining trusted science, consumer insight and global scale, Veet has evolved from a single depilatory cream into…

3 minutes read

Gaviscon Double Action products in mint and peppermint flavours

News

02 Sep 2026

From A Simple Scientific Question To The World’s Go-To Heartburn & Indigestion Brand

How Gaviscon grew to define digestive self-care

4 minutes read

Children and community members at a Dettol Climate Resilient School in India

News

10 Aug 2026

How Dettol’s Climate Resilient Schools Programme is improving child health in India

5 minutes read

A box of Mucinex 12HR Cold & Fever Multi-Symptom medicine centered on a vibrant pink background, surrounded by four large bi-layer tablets

News

05 Aug 2026

Reckitt Announces U.S. FDA Approval of Mucinex 12HR Cold & Fever Multi-Symptom, the First OTC Innovation in the Cold & Flu Category in 14 Years

Company’s First New Drug Approval Addresses #1 Unmet Need for Long-Lasting Symptom Relief*

5 minutes read

Worker sorting red lozenges on a production line next to a Strepsils tin

Brands

09 Jun 2026

How unique science and consumer obsession are expanding Strepsils’ reach

A new era of dual action science is taking Strepsils beyond sore throat

5 minutes read

Collage of Dettol cleaning and skincare products with family photos.

Brands

09 Jan 2026

Dettol - A legacy of global impact

Lifting the lid on the past, present and future of one of the world’s most trusted brands

4 minutes read

Meet Our Powerbrands

Brands

03 Apr 2025

Meet Our Powerbrands

The Foundations for Success

5 minutes read

Lysol Air Sanitizer scoops a R&D100 Award!

Brands

02 Sep 2024

Lysol Air Sanitizer scoops a R&D100 Award!

103 - 105 Bath Road, Slough Berkshire, SL1 3UH


© Reckitt 2026 All Rights Reserved

Edit

Cookies On This Site

We, RB UK Commercial Limited., use essential cookies to enable this site to function and to save some of your preferences.  We and our partners also use other, non-essential cookies and similar technologies to enhance the site’s functionality, improve your browsing experience, perform analytics, and offer you personalised advertising. You can accept all non-essential cookies, reject all non-essential cookies, or select “Manage cookie preferences” below for further options and information. We will retain your choice for 13 months. In the case of ”Essential” cookies, we automatically place them as permitted by applicable law.  To learn more about our cookie usage and how you can change your cookie settings, please read our Cookie Policy. To change your preferences, click on the green cookie icon at the bottom left of our site at any time.

Accept Non-Essential Cookies

Reject Non-Essential​ Cookies

Manage Preferences

Company Logo

Privacy Preference Centre

Privacy Preference Centre

  • About Cookies On This Site

  • Essential Cookies

  • Analytics Cookies

  • Advertising Cookies

About Cookies On This Site

We, RB UK Commercial Limited., use essential cookies to enable this site to function and to save some of your preferences.  We and our partners also use other, non-essential cookies and similar technologies to enhance the site’s functionality, improve your browsing experience, perform analytics, and offer you personalised advertising. You can accept all non-essential cookies, reject all non-essential cookies, or select “Manage cookie preferences” below for further options and information. We will retain your choice for 13 months. In the case of ”Essential” cookies, we automatically place them as permitted by applicable law.  To learn more about our cookie usage and how you can change your cookie settings, please read our Cookie Policy.   To change your preferences, click on the green cookie icon at the bottom left of our site at any time. 

Third-Party Partners

We work with trusted third-party partners. See below for more details on each.

Google

Purpose: Site functionality, visitor statistics, site traffic analysis, analysis of online user browsing behaviour

Privacy Policy: https://policies.google.com/privacy

Essential Cookies

Always Active

We use essential cookies to make our site work.  These cookies enable core site functionality, ensure the site is secure, allow us to manage the network and manage your consent preferences. These cookies cannot be disabled because without these cookies, the site cannot function properly. For example, these cookies may be used for site navigation, ensuring online forms work, allowing you to log in, or remembering your consent preferences.

Cookie Details

Analytics Cookies

Analytics Cookies

These cookies allow us to monitor our site usage. They count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.   If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

Cookie Details

Advertising Cookies

Advertising Cookies

These cookies may be set up by us or by our advertising partners. These cookies allow us or our partners to build a profile of your interests and show you relevant adverts on other sites.  The use of these cookies may involve tracking, targeting, and re-engaging you across multiple sites and social networks. If you disable these cookies, you will still see advertisements, however, they will not be personalised to your interests. 

Cookie Details

Back Button

Vendors List

Filter Button

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Confirm My Choices

Reject Non-Essential​ Cookies Accept Non-Essential Cookies

Powered by Onetrust

Prompts

Reckitt Benckiser Group plc (ticker RKT), listed in United Kingdom.

ETFs Holding Reckitt Benckiser Group plc

ETF Weight in ETF Shares Market value As of
DIVS 2.15% 12,695 $ 826.946K Jun 30, 2026
FEOE 1.74% 475,598 $ 33.072M Aug 31, 2026
THOR 1.52% 5,185 $ 360.558K Aug 31, 2026
FEGE 1.14% 411,896 $ 28.643M Aug 31, 2026
RFDI 1.10% 25,705 $ 1.815M Jul 31, 2026
AIVI 1.07% 9,631 $ 627.76K Jun 30, 2026
ILOW 0.96% 257,863 $ 17.942M Aug 31, 2026
IVSI 0.89% 1,082 $ 70.484K Jun 30, 2026
DIHP 0.68% 597,439 $ 44.826M Nov 12, 2026
NBIE 0.67% 24,477 $ 1.69M Aug 31, 2026
RINT 0.62% 13,342 $ 869.124K Jun 30, 2026
SEIE 0.49% 85,645.84 $ 5.582M Jun 30, 2026
TXUE 0.46% 36,646 $ 2.55M Aug 31, 2026
UMMA 0.40% 16,980 $ 1.181M Aug 31, 2026
RGLO 0.35% 18,312 $ 1.193M Jun 30, 2026
DXIV 0.34% 10,978 $ 823.681K Nov 12, 2026
AVSD 0.33% 16,056 $ 1.22M Nov 16, 2026
DFSI 0.28% 43,670 $ 3.277M Nov 12, 2026
AVDE 0.22% 567,801 $ 43.148M Nov 16, 2026
JSTC 0.21% 8,228 $ 626.856K Nov 17, 2026
NTSI 0.20% 14,973 $ 975.958K Jun 30, 2026
DFAI 0.18% 444,492 $ 33.35M Nov 12, 2026
DFIC 0.16% 338,686 $ 25.412M Nov 12, 2026
GEW 0.15% 3,187 $ 221.619K Aug 31, 2026
TIER 0.12% 614 $ 43.335K Jul 31, 2026
DFAX 0.06% 102,135 $ 7.663M Nov 12, 2026